10-Q: Astrana Health Q2 Revenue Soars 35% Amid Acquisitions

Astrana Health reports significant revenue growth driven by recent acquisitions, despite a decline in net income and operating profit for the second quarter and first half of 2025.

Summary

• Total revenue for the three months ended June 30, 2025, increased by 35% to $654.8 million, up from $486.3 million in the prior year period.
• Total revenue for the six months ended June 30, 2025, rose by 43% to $1.275 billion, compared to $890.6 million in the same period of 2024.
• Capitation revenue, a primary driver, increased by $171.5 million (39%) for the three-month period and $389.6 million (48%) for the six-month period, largely due to recent acquisitions and enrollees transitioning to full risk plans.
• Net income attributable to Astrana Health, Inc. decreased by 51% to $9.4 million for the three months ended June 30, 2025, from $19.2 million in 2024.
• Net income attributable to Astrana Health, Inc. for the six months ended June 30, 2025, fell by 53% to $16.1 million, from $34.0 million in 2024.
• Operating income declined by 32% to $20.3 million for the three-month period and by 32% to $40.9 million for the six-month period.
• Adjusted EBITDA for the three months ended June 30, 2025, saw a slight increase of 0.4% to $48.1 million, while for the six months, it decreased by 6% to $84.5 million.
• Adjusted EBITDA margin was 7% for both the three and six months ended June 30, 2025, down from 10% in the prior year periods.
• Cash provided by operating activities significantly increased to $107.5 million for the six months ended June 30, 2025, up from $29.2 million in 2024, primarily due to favorable changes in working capital.
• The company completed the acquisition of Prospect Health Plan, Inc. and certain assets of Prospect Medical Holdings, Inc. on July 1, 2025, for $707.9 million in cash, financed by a delayed draw term loan.
• Following the Prospect acquisition, Astrana now supports over 20,000 providers and more than 1.6 million patients.
• The company managed 21 independent risk-bearing organizations as of June 30, 2025, up from 18 in the prior year.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While revenue growth is strong due to acquisitions, profitability metrics (net income, operating income, Adjusted EBITDA margin) have declined significantly. The substantial increase in operating cash flow is a positive, but new risks related to regulatory changes and the bankruptcy of an acquired entity's affiliates introduce uncertainty. The large acquisition is a strategic positive but also carries integration and financial risks.

Positives

• Achieved substantial revenue growth of 35% for the quarter and 43% for the six-month period, primarily driven by strategic acquisitions and increased capitation revenue.
• Significantly improved net cash provided by operating activities, which increased by 269% to $107.5 million for the six months ended June 30, 2025.
• Successfully completed the Prospect Transaction, expanding its network to over 20,000 providers and more than 1.6 million patients, enhancing its integrated care delivery model.
• Increased the number of managed independent risk-bearing organizations to 21, demonstrating continued network expansion.
• Reduced interest expense by 14% for the quarter and 9% for the six-month period due to lower interest rates on floating-rate debt and a decrease in outstanding borrowings.

Negatives

• Experienced a significant decline in net income attributable to Astrana Health, Inc., down 51% for the quarter and 53% for the six-month period.
• Operating income decreased by 32% for both the three and six-month periods.
• Adjusted EBITDA for the six-month period decreased by 6%, and the Adjusted EBITDA margin declined from 10% to 7% compared to the prior year.
• General and administrative expenses increased by 41% for the quarter and 27% for the six-month period, primarily due to operational growth support, stock-based compensation, and transaction costs for the Prospect acquisition.
• Interest income decreased by 34% for the quarter and 38% for the six-month period due to a decrease in cash held in interest-bearing bank accounts.
• Other income (loss) saw a substantial decrease, primarily due to non-recurring reimbursement in the prior year and debt issuance costs expensed in the current period.

Risks

• The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, introduces Medicaid work-requirement pilots and tighter provider-tax rules, which could reduce patient population and managed care enrollees due to stricter eligibility requirements (e.g., work/community service, copayments, immigration enforcement).
• OBBBA may lead to higher volumes of uncompensated emergency admissions of uninsured individuals at Foothill Regional Medical Center (FRMC), which was acquired in the Prospect Transaction.
• Medicaid provider tax reform targeted by the current administration could reduce FRMC revenues, potentially forcing reductions or closures of hospital services.
• The bankruptcy filing of certain Prospect asset seller entities (Prospect PhysicianCo Entities) on July 7, 2025, could result in their breach or noncompliance with contractual obligations, potentially requiring Astrana to absorb related costs with limited recourse due to the elimination of the escrow account and recourse exceptions.

Future Outlook

The company believes it has sufficient liquidity to fund operations for at least the next 12 months and the foreseeable future. It is evaluating the full downstream effects of the One Big Beautiful Bill Act (OBBBA) but believes it is well-positioned to navigate these changes, viewing them as manageable headwinds due to its diversified footprint, strong Medicaid performance, and care-enablement infrastructure. The company also anticipates potential impacts from the bankruptcy of certain Prospect asset seller entities, which could necessitate absorbing costs with limited recourse.

Management Comments

• "We believe Astrana is well-positioned to navigate these changes and view these headwinds as manageable."

Industry Context

Astrana Health operates in the U.S. healthcare industry, specifically focusing on value-based care arrangements, which are increasingly emphasized by government programs like Medicare and Medicaid. The recent acquisition of Prospect significantly expands its integrated care delivery network across multiple states, positioning it as a larger player in the value-based care space. However, the industry faces regulatory changes, such as the One Big Beautiful Bill Act, which could impact patient eligibility and provider funding, potentially affecting companies reliant on government programs. The bankruptcy of a key acquisition target's related entities highlights the financial complexities and risks inherent in large-scale healthcare transactions and the broader financial health of some industry participants.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. However, the company's expansion through acquisitions, such as Prospect Medical Holdings, Inc., aligns with a broader industry trend of consolidation and vertical integration among healthcare providers and payers seeking to enhance value-based care capabilities and expand geographic reach. The decline in net income despite significant revenue growth suggests potential integration costs or increased operational expenses, which can be common during periods of rapid acquisition-driven expansion in the healthcare sector. The increase in operating cash flow is a positive indicator, suggesting improved operational efficiency in cash generation, which is crucial for sustaining growth and managing debt in a capital-intensive industry.

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business.
• Management does not believe the company is a party to any legal proceedings that would have a material adverse effect on its operations.
• The resolution of any claim or litigation is inherently uncertain and could impact the company's financial condition, cash flows, or results of operations.

Related Party Transactions

• Payments of approximately $3.8 million for the six months ended June 30, 2025, to equity method investments for management fee services, provider services, and interest expense.
• Received $0.9 million in management fees from equity method investments during the six months ended June 30, 2025.
• Incurred rent expenses of approximately $2.5 million for the six months ended June 30, 2025, from properties managed by Allied Pacific Holdings Investment Management, LLC, whose CEO is a board member.
• Incurred approximately $5.2 million in expenses for call center and credentialing services from Third Way Health, where one of Astrana's officers is a board member.
• Recognized net loss of $66.655 million for the six months ended June 30, 2025, from transactions with AHMC Healthcare Inc., where one director is an officer and two directors serve on the board.
• Recognized risk pool revenues of $7.8 million for the six months ended June 30, 2025, from a risk-sharing agreement with certain AHMC hospitals.
• Paid an aggregate of approximately $9.2 million for the six months ended June 30, 2025, to board members for provider services, including $1.2 million to Astrana board members/officers who are also APC board members/officers.

Stakeholder Impact

• **Shareholders:** Potential for increased long-term value through strategic acquisitions and expanded market reach, but short-term profitability declines and new risks (regulatory, bankruptcy of acquired entity's affiliates) could impact share price and investor confidence.
• **Employees:** The Prospect acquisition expands the workforce, but the bankruptcy of Prospect PhysicianCo Entities and potential WARN Act liabilities introduce uncertainty for some employees. The company is providing payroll and benefits transition support.
• **Customers (Patients):** Expanded network and integrated care delivery model aim to provide high-quality, cost-effective care to a larger patient base (over 1.6 million patients post-acquisition). However, regulatory changes like OBBBA could affect patient eligibility and access to services.
• **Providers:** The company's focus on empowering providers in value-based care arrangements and expanding its network (over 20,000 providers post-acquisition) offers growth opportunities and support. However, changes in Medicaid/Medicare funding could impact provider payment rates.
• **Creditors:** The company's debt structure has been refinanced with new credit facilities, and a significant portion of the delayed draw term loan was utilized for the Prospect acquisition, increasing leverage. However, improved operating cash flow provides a stronger basis for debt servicing.

Next Steps

• Continue to evaluate the full downstream effects of the One Big Beautiful Bill Act (OBBBA) and navigate its changes.
• Integrate the acquired Prospect businesses and assets, including managing the transition of employees and systems.
• Monitor and manage potential costs and liabilities arising from the Chapter 11 bankruptcy filing of the Prospect PhysicianCo Entities.
• Continue to comply with financial ratios and covenants under the Second Amended and Restated Credit Agreement.
• Manage the repayment schedule for the company's debt, with future commitments extending through 2029 and thereafter.

Key Dates

Recommendation

Astrana Health's Q2 2025 filing presents a mixed financial picture. While the company achieved substantial revenue growth driven by strategic acquisitions, particularly the Prospect Transaction, its net income and operating profit have significantly declined. The increase in operating cash flow is a positive sign of operational efficiency. However, new risks, including the potential adverse effects of the One Big Beautiful Bill Act on patient populations and revenues, and the bankruptcy filing of the Prospect seller entities, introduce considerable uncertainty and potential liabilities. The large acquisition, while strategically important for market expansion, also brings integration challenges and financial risks. Given the strong revenue growth offset by declining profitability and emerging risks, a 'hold' recommendation is appropriate as investors should monitor how the company navigates these challenges and integrates its new assets to realize the full benefits of its expansion.

Keywords

Healthcare, Value-based care, SEC filing, 10-Q, Managed care, Medicare, Medicaid, Acquisition, Financial results, Risk-bearing organization, Provider network, Health plan